usdaed

The question, naturally, is whether this presents an opportunity. A chance to acquire a piece of the future before the masses once again succumb to speculative fervor? In short, yes. Now is precisely the moment to add Nvidia shares to one’s portfolio. Not, mind you, because of any inherent faith in technological progress – though that is a pleasant side effect – but because a clever investor always buys when others are counting their losses.

Now, Borr Drilling, for the uninitiated, is in the business of sticking pointy things into the seabed.¹ Specifically, jack-up rigs – those sturdy platforms that raise themselves on legs to avoid getting their keels scraped. They’re the workhorses of shallow-water oil and gas extraction. A decidedly unglamorous profession, but one that, rather surprisingly, is currently enjoying a renaissance. Years of… shall we say, fiscal prudence (read: underinvestment) have left a gap in the market, and Borr is positioning itself to fill it.

By the close of trading, Tandem’s stock was up over 32%. Which, in the grand scheme of things, is a decent showing. It’s enough to make one briefly consider a career in glucose monitoring, before remembering the inherent complexities of endocrinology.

Tuya, as near as I can tell, is the plumbing of the smart home. They don’t make the shiny objects; they make the stuff that lets the shiny objects talk to each other. It’s like being the stage crew at a really elaborate, slightly terrifying puppet show. They have this AI cloud platform that lets companies build connected devices without, you know, actually building the entire software infrastructure. It’s efficient, and it’s remarkably unglamorous. Which, again, is a plus.

Based in Portland, Oregon – a place known for its coffee and, increasingly, its attempts to solve the world’s energy problems – NuScale currently holds the singular honour (and, let’s be frank, the considerable pressure) of being the only U.S. nuclear firm with approval from the Nuclear Regulatory Commission (NRC) for these Small Modular Reactors, or SMRs. There’s a whole host of other startups – Oklo, Nano Nuclear Energy, and a few others operating on what can only be described as optimistic projections – but NuScale is the only one with a license to actually deploy the things on a commercial scale. It’s a bit like being the only blacksmith in a town that’s suddenly decided everyone needs swords. Good for business, potentially. But also a lot of responsibility.

The current insistence on robust health feels… premature. The indicators, while not yet screaming, emit a persistent, low-frequency hum that suggests a fragility beneath the surface. The following observations, presented not as predictions, but as the cataloging of certain… tendencies, may prove instructive, or merely add to the general confusion. It is, after all, the nature of systems to resist simple categorization.

I’ve made a list, actually. A list of things I’m supposed to be doing with my money. 1. Pay off student loans. 2. Invest for the future. 3. Not buy another pair of boots I don’t need. ExxonMobil is, theoretically, item number two. It’s been paying dividends for 43 years, which is… reassuring. In this economy, longevity feels like a superpower.

Yet, amidst this minor catastrophe, a glimmer of…something. The introduction of an oral version of Wegovy, a drug designed to wrestle with the very essence of human gluttony. A pill, you see, instead of a needle. A small victory for those who harbor a deep, irrational fear of sharp objects, and a considerable convenience for travelers, who, as any seasoned observer of humanity knows, are prone to indulging in excesses of both scenery and pastry. And it is here that a curious tale unfolds, a tale whispered from the lips of none other than Eli Lilly.